

14:10-14:40 Opening Lecture

Chair : Paula Alba (Cordoba Hospital)

Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR))

OL-1 Challenges in the diagnosis of obstetric antiphospholipid syndrome

Mayumi Sugiura-Ogasawara

Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan

OL-2 Antiphospholipid antibody testing: evolving from a diagnostic tool to a risk assessment marker

Tatsuya Atsumi

Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine, Hokkaido University, Sapporo, Japan

14:50-15:20 Plenary Lecture 1

Chair : Angela Tincani (ASST-Spedali Civili and University of Brescia)

PL1 The History of Antiphospholipid Antibodies

Robert A. S. Roubey

Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, USA

15:30-16:50 Workshop 1: Thrombotic APS: Insights into Mechanisms of Thrombosis

Chair : Philip de Groot (Synapse Research Institute)

Vittorio Pengo (University of Padova School of Medicine)

WS1-1(L) Structural basis of prothrombin recognition by anti-prothrombin antibodies: mechanisms, function, and detection

Nicola Pozzi

Saint Louis University School of Medicine, Saint Louis, USA

WS1-2(L) Initiation of Tissue Factor dependent thrombosis by antiphospholipid antibodies

Wolfram Ruf

Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany

WS1-3(A) Association between the active form of plasminogen activator inhibitor 1 (PAI-1) and endothelial cell activation in antiphospholipid syndrome

Yuzhou Gan

Division of Rheumatology, University of Michigan, Ann Arbor, USA/Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, PRC

WS1-4(A) Beyond Domain I: anti- β 2GPI IgG display a broad reactivity against different molecule domains

Pierluigi Meroni

IRCCS Istituto Auxologico Italiano, Milan, Italy

L = Lecture (20 min), A = Abstract (15 min)

17:00-18:20 Workshop 3: Pathogenesis of Obstetric APS

Chair : Mayumi Sugiura-Ogasawara (Nagoya City University)

Ware Branch (University of Utah)

WS3-1(L) Pathogenesis of Obstetric Antiphospholipid Syndrome

Guilherme Ramires de Jesús

Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

WS3-2(L) β 2-glycoprotein I neo self-antibody is associated with the pathogenesis of obstetric antiphospholipid syndrome

Kenji Tanimura

Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan

WS3-3(A) Activated protein C sensitivity assessed with thrombin generation assay in antiphospholipid syndrome patients with obstetric complications: results from two prospective cohorts and perspectives

Thomas Foret

CHU-Besançon, Vascular Medicine Unit, Besançon, France/University of Franche-Comté, SINERGIES, Besançon, France

WS3-4(A) COVID-19 infection or COVID-19 mRNA vaccination does not induce antiphospholipid antibodies in women with recurrent pregnancy loss

Toshiyuki Takeshita

Takeshita Ladies Clinic, Tokyo, Japan

L = Lecture (20 min), A = Abstract (15 min)

18:30-19:10 Honorary Lecture

Chair : Takao Koike (Hokkaido University)

HL Shaping Our Understanding of Antiphospholipid Syndrome

Graham Hughes

London Lupus Centre, UK

15:30-16:50 **Workshop 2: Lupus Anticoagulant: Current Insights and Clinical Implications**

Chair : Jacob Rand (Weill Cornell Medical College)

Thomas Ortel (Duke Health)

WS2-1(L) Crosstalk between Lupus anticoagulant and autoantibodies to coagulation factors

Masahiro Ieko

Sapporo University of Health Sciences, Sapporo, Japan

WS2-2(L) Challenges in lupus anticoagulant detection

Gary W Moore

Specialist Haemostasis Unit, Cambridge University Hospitals, Cambridge, United Kingdom/Department of Natural Sciences, Middlesex University London, London, United Kingdom

WS2-3(A) Individual correction formulas re-enable reliable Point-of-Care INR monitoring in high-risk antiphospholipid syndrome

Maarten Limper

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

WS2-4(A) Semi-Quantitative Lupus Anticoagulant Assay and Its Application in Thrombosis Risk Stratification for Antiphospholipid Syndrome

Yuta Inoue

Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

L = Lecture (20 min), A = Abstract (15 min)

17:00-18:20 **Workshop 4: The Complexities of Stroke in APS**

Chair : Steven Levine (SUNY Downstate Health Sciences University)

Olga Amengual (Hokkaido University)

WS4-1(L) Stroke in Antiphospholipid Syndrome: Clinical Insights and Therapeutic Implications

Yuichiro Fujieda

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

WS4-2(L) Stroke from a Neurologist's Perspective

María Alonso de Leciñana

Neurology, University Hospital La Paz. IdiPAZ. Universidad Autónoma de Madrid, Madrid, Spain

WS4-3(A) Prevalence of Silent Brain and Cardiac Microvascular Lesions in Primary Antiphospholipid Syndrome: A Pilot Multiorgan MRI Study

Denis Wahl

University of Lorraine

**WS4-4(A) Intracranial Arterial Stenosis in Antiphospholipid Syndrome:
A Neglected Vascular Involvement?**

Yuying Fan

Department of rheumatology and immunology, Shanghai Jiao Tong University
School of Medicine Affiliated Ruijin Hospital, Shanghai, China

L = Lecture (20 min), A = Abstract (15 min)

09:00-10:00 Symposium 1: Anti-phosphatidylserine/prothrombin (aPS/PT) Antibody

Chair : Pier Luigi Meroni (IRCCS Istituto Auxologico Italiano)

S1-1(A) Clinical relevance of isolated anti-phosphatidylserine/prothrombin antibody positivity

Polona Žigon

Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenija／Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Koper, Slovenia

S1-2 Thrombogenic characteristics of anti-D1- β 2GPI and anti-PS/PT IgG in a rat model of vascular APS

Meroni PL

Laboratory of Immuno-Rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy

S1-3 Debate: aPS/PT - A Necessary Tool or an Uncertain Practice?

Maria Laura Bertolaccini
Doruk Erkan

King's College London
Hospital for Special Surgery, New York, USA

10:10-11:30 Sponsored Symposium 1

Chair : Takao Fujii (Wakayama Medical University)

SS1-1 Interferon Signatures and Antiphospholipid Antibodies: Toward Precision Risk Stratification in Patients with Antiphospholipid Syndrome

Yuichiro Fujieda

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

SS1-2 Roles of Cytokines and Autoantibodies in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

Yoshiyuki Arinuma

Department of Rheumatology, Mie University Graduate School of Medicine, Mie, Japan／Department of Rheumatology, Center for Rheumatic diseases, Mie University Hospital, Mie, Japan

Co-Sponsored by AstraZeneca K.K.

11:40-12:20 Plenary Lecture 2

Chair : Tatsuya Atsumi (Hokkaido University)

PL2 COVID-19, Post-COVID Syndrome SLE and Autoimmunity

Yehuda Shoenfeld

Reichman University, Herzlia, Israel, Sheba Medical Center

12:30-13:20 **Luncheon Seminar 1**

Chair : Shinsuke Yasuda (Institute of Science Tokyo)

LS1 Therapeutic Strategies and Challenges in Lupus Nephritis

Hironari Hanaoka

Rheumatology and Clinical Immunology, Saitama Medical University, Kawagoe, Japan

Co-Sponsored by Otsuka Pharmaceutical Co., Ltd.

13:40-15:00 **Workshop 5: aCL and anti β 2GPI in the Laboratory: Optimizing Laboratory Methods**

Chair : Pier Luigi Meroni (IRCCS Istituto Auxologico Italiano)

Yuichiro Fujieda (Keio University)

**WS5-1(L) QUANTA Flash CLIA: ELISA-comparable moderate and high thresholds for anticardiolipin and anti- β 2GPI antibodies
Implementation of the 2023 ACR/EULAR APS classification criteria in practice**

Polona Žigon

Department of rheumatology, University medical centre Ljubljana, Ljubljana, Slovenija/Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Koper, Slovenija

**WS5-2(L) Self and Neoself Discrimination by T Cells in Autoimmunity:
The Diagnostic Value of Neoself β 2-Glycoprotein I in Antiphospholipid Syndrome**

Hisashi Arase

Immunochemistry, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan

WS5-3(A) Audit and Review of Anti-Phospholipid Antibody Testing in a Tertiary Academic Pediatric Center

Rehana Saleem

Sidra Medicine, Doha, Qatar

WS5-4(A) Prevalence of antiphospholipid antibodies in the GLADEL 2.0 multi-national and ethnically diverse cohort assessed with a novel particle-based multi-analyte technology

Guillermo Pons-Estel

Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina

L = Lecture (20 min), A = Abstract (15 min)

15:10-16:30 **Sponsored Symposium 3**

Chair : Laura Martinez-Prat

SS3-1 Autoantibody Detection in APS: Recent Advances and Clinical Implications

Laura Martinez-Prat

R&D, Scientific & Clinical Affairs, Werfen, Barcelona, Spain

SS3-2 New Frontiers in aPL Research and Diagnostics

Maria Laura Bertolaccini King's College London School of Life Sciences and Medicine, St. Thomas' Hospital, London, UK

SS3-3 Phosphatidylserine-dependent Antiprothrombin Antibodies in Antiphospholipid Syndrome: Biology, Clinical Utility, and a Roadmap for Clinical Adoption

Yuichiro Fujieda Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Co-Sponsored by Werfen

16:40-18:00 Workshop 7: Thrombotic APS: Navigating Treatment Challenges

Chair : Danieli Andrade (University of São Paulo)

Masataka Kuwana (Nippon Medical School)

WS7-1(L) Antiphospholipid Antibodies in SLE

Michelle Petri Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, United States

WS7-2(L) Thrombotic APS: Navigating Treatment Challenges

Hannah Cohen Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom/Department of Haematology, Cancer Institute, University College London, London, United Kingdom

WS7-3(A) Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Real-Life Experience

Ariela Hoxha Department of Medicine - DIMED, Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED, University of Padua, Padua, Italy

WS7-4(A) Open-label, Prospective, Phase II Descriptive Pilot Trial of Belimumab Therapy for Refractory and/or Non-criteria Manifestations of Antiphospholipid Syndrome: Clinical Interim Results

Irene Cecchi Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

L = Lecture (20 min), A = Abstract (15 min)

09:00-10:00 **Symposium 2: Strengthening Clinical Rheumatology: Collaborative Approaches and New Frontiers**

Chair : Takao Fujii (Wakayama Medical University)

Akio Morinobu (Kyoto University)

S2-1 Collaboration under pandemic leading to a possible novel therapy for APS

Shinsuke Yasuda Department of Rheumatology, Institute of Science Tokyo, Tokyo, Japan

**S2-2 Strengthening Clinical Rheumatology:
Antinuclear Antibodies in Systemic Autoimmune Rheumatic Diseases**

Takao Fujii Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan

S2-3 Management of Pregnancy in Systemic Lupus Erythematosus

Kayoko Kaneko Division of Maternal medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan

10:10-11:30 **Sponsored Symposium 2**

Chair : Shinsuke Yasuda (Institute of Science Tokyo)

SS2-1 Thrombosis, cytokine storm, and antiphospholipid antibody in COVID-19

Tadashi Hosoya Department of Rheumatology and Collagen Diseases, Institute of SCIENCE TOKYO, Tokyo, Japan／Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan

SS2-2 Deep-Dive into Macrovascular Antiphospholipid Syndrome: Still an enigma

Zhao Jiuliang Department of rheumatology and clinical immunology, Peking Union Medical college Hospital, Beijing, China

Co-Sponsored by Shenzhen YHLO Biotech

12:30-13:20 **Luncheon Seminar 2**

Chair : Eriko Morishita (Kanazawa University)

LS2 Thrombocytopenia and Thrombosis in Antiphospholipid Syndrome and Immune Thrombocytopenia: An Interconnected Pathogenesis

Kenji Oku Tokai University School of Medicine, Isehara, Japan

Co-Sponsored by argenx Japan K.K.

13:40-15:00 **Workshop 6: Catastrophic APS: Current Challenges and Emerging Therapeutic Approaches**

Chair : Giovanni Sanna (Guy's Hospital)

Ricard Cervera (Hospital Clínic de Barcelona / University of Barcelona)

WS6-1(L) Catastrophic antiphospholipid syndrom: Emerging therapeutic approach

Ricard Cervera

Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain

WS6-2(L) Clinical Manifestations of Catastrophic Antiphospholipid Syndrome: A Comprehensive Overview

Ignasi Rodriguez Pintó

Department of Autoimmune Disease, Hospital Clinic, Barcelona, Spain

WS6-3(A) A Phase 1b Basket Trial of RAY121, A Novel Recycling Monoclonal Antibody Against Complement C1s in Antiphospholipid Syndrome and Complement-mediated Autoimmune Diseases

Doruk Erkan

Hospital for Special Surgery, New York, USA

WS6-4(A) Risk Factors for Antiphospholipid Syndrome-associated Nephropathy (APSN): A Retrospective Cohort Analysis

Xiaohan Wei

Department of Rheumatology and Immunology, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China

L = Lecture (20 min), A = Abstract (15 min)

15:10-16:30 **Sponsored Symposium 4**

Chair : Kenji Oku (Tokai University)

SS4-1 Recent advances in the pathogenesis of systemic lupus erythematosus

Michihito Kono

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University

SS4-2 Elucidation of immunological pathways associated with disease activity and flare in SLE

Keishi Fujio

Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo

Co-Sponsored by CHUGAI PHARMACEUTICAL CO.,LTD.

16:40-18:00 **Workshop 8: Obstetric APS: Treatment**

Chair : Mariëtte Goddijn (Amsterdam UMC)

Toshiyuki Takeshita (Takeshita Ladies Clinic)

WS8-1(L) Definitions, frequencies and treatment of APS in a Danish RPL setting

Henriette Svarre Nielsen

Dept. of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark

WS8-2(L) Treatments of recurrent pregnancy loss and infertility in women with neoself antibody (anti- β 2GPI/HLA-DR)

Hideto Yamada

Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital, Sapporo, Japan

WS8-3(A) Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): Results from ongoing recruitment

Jane E Salmon

Hospital for Special Surgery, New York, United States of America/Weill Cornell Medicine, New York, United States of America

WS8-4(A) Hydroxychloroquine Improves Obstetric Outcomes in Refractory Obstetric Antiphospholipid Syndrome: Results from a Large Cohort

Mariela Gerde

Department of Obstetrics and Gynecology, Austral University Hospital, Buenos Aires, Argentina

L = Lecture (20 min), A = Abstract (15 min)

09:00-10:20 **Workshop 9: Tracking APS Disease Activity**

Chair : Maria Tektonidou (National and Kapodistrian University of Athens)
David Isenberg (University College London)

WS9-1(L) Development and validation of a disease activity score for antiphospholipid syndrome and its implementation in clinical practice

MARIA TEKTONIDOU National and Kapodistrian University of Athens, ATHENS, GREECE

WS9-2(L) Non-Thrombotic, Non-Obstetric Manifestations of APS: Unmasking Disease Activity Beyond the Classic Presentation

Savino Sciascia University of Torino, Torino, Italy

WS9-3(A) Cardiovascular risk factor control in the SURvey of cardiovascular disease Risk Factors (SURF) in Systemic lupus erythematosus and Antiphospholipid syndrome (APS) project including 1003 patients with APS

Maria G. Tektonidou Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece

WS9-4(A) Patients with antiphospholipid syndrome and recurrent thrombosis have significantly impaired endothelial function and evidence impaired fibrinolysis

Deepa J Arachchilage Centre for Haematology, Imperial College London, London, United Kingdom/Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

L = Lecture (20 min), A = Abstract (15 min)

10:30-11:50 **Sponsored Symposium 5**

Chair : Tatsuya Atsumi (Hokkaido University)
Mayumi Sugiura-Ogasawara (Nagoya City University)

SS5-1 Diagnosis and biomarkers of thrombotic APS

Savino Sciascia Department of Clinical and Biological Sciences and Medicine and Surgery, University of Turin, Turin, Italy

SS5-2 Obstetric Antiphospholipid Syndrome: Patient Perspectives from the Recurrent Pregnancy Loss Outpatient Clinic

Mariëtte Goddijn Amsterdam Reproduction & Development (AR&D) and Center for Reproductive Medicine, Amsterdam UMC, Amsterdam, Netherlands

Co-Sponsored by MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

12:10-13:00 **Luncheon Seminar 3**

Chair : Tatsuya Atsumi (Hokkaido University)

LS3 Management of Pregnancy in Women with Systemic Lupus Erythematosus and Antiphospholipid Syndrome: Advances and Challenges

Kayoko Kaneko

Division of Maternal medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan

Co-Sponsored by GlaxoSmithKline K.K.

13:20-14:40 **Workshop 11: β 2GPI and Autoimmunity: Insights into Immunological Pathways and Disease Mechanisms**

Chair : Steve Krilis (St. George Hospital, University of New South Wales)

Eiji Matsuura (Okayama University)

WS11-1(L) The Role of Redox and Posttranslational Modification of Beta-2 Glycoprotein I in Antiphospholipid Syndrome

Steve Krilis

University of New South Wales Saint George Hospital, Sydney, Australia

WS11-2(L) β 2-glycoprotein I: Structure and Deciphering Pathogenic Mechanisms in Antiphospholipid Syndrome

Eiji Matsuura

Okayama University, Okayama, Japan

WS11-3(A) The J-shape of β 2GPI Reveals a Cryptic Discontinuous Epitope Across Domains I and I

Christophe J Lalaurie

Department of Ageing, Rheumatology & Regenerative Medecine, University College London, London, United Kingdom

WS11-4(A) A proteolysis-resistant domain V's variant of β 2-glycoprotein I: as a novel therapeutic tool to prevent thrombosis in antiphospholipid syndrome

Daisuke Kawata

Department of Rheumatology, Institute of Science Tokyo, Tokyo, Japan

L = Lecture (20 min), A = Abstract (15 min)

15:20-16:00 **Plenary Lecture 3**

Chair : Mayumi Sugiura-Ogasawara (Nagoya City University)

PL3 Obstetric Antiphospholipid Syndrome

Ware Branch

Obstetrics and Gynecology, University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, Utah, USA

Chair : Hannah Cohen (University College London Hospitals and University College London)

Katrien Devreese (Ghent University Hospital)

S3-1 Update on laboratory detection and interpretation of aPL for diagnosis of APS

Katrien MJ Devreese Ghent University Hospital, Gent, Belgium

S3-2 Harmonization in aPL testing: problems and solutions

Meroni PL Laboratory of Immuno-Rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy

S3-3 Assessment of impaired fibrinolysis in patients with antiphospholipid syndrome

Deepa J Arachchillage Centre for Haematology, Department Immunology and Inflammation, Imperial College London, London, United Kingdom

09:00-10:20 **Workshop 10: Epidemiology and Organ Involvement in Antiphospholipid Syndrome**

Chair : Bernardo Pons-Estel (Regional Center for Autoimmune and Rheumatic Diseases (CREAR))

Mary-Carmen Amigo (ABC Medical Center)

WS10-1(L) Heart valve disease in patients with APS: a high-risk subgroup

Mary-Carmen Amigo Department of Rheumatology, ABC Medical Center, Mexico City, Mexico

WS10-2(L) Thrombocytopenia in Antiphospholipid Syndrome: Clinical Significance and Therapeutic Perspectives

Ryo Hisada Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

WS10-3(A) CLINICAL MANIFESTATIONS AND OUTCOMES OF FILIPINO PATIENTS WITH ANTI-PHOSPHOLIPID SYNDROME: A TERTIARY PRIVATE HOSPITAL STUDY

Cristina A. Dorado Section of Rheumatology, St. Luke's Medical Center, Quezon City, Philippines

WS10-4(A) Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome

Ecem Sevim National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health, Bethesda, United States/National Heart, Lung, and Blood Institute; National Institutes of Health, Bethesda, United States

L = Lecture (20 min), A = Abstract (15 min)

10:30-11:50 **Special Workshop: What's New in APS ACTION: Recent Breakthroughs and Future Directions**

Chair : Doruk Erkan (Hospital for Special Surgery)

Danieli Andrade (University of São Paulo)

SWS-1(L) What Did APS ACTION Achieve in the Last 15 Years and the Forecast for the Next 15 Years?

Doruk Erkan Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA

SWS-2(L) A Glimpse of APS ACTION's Research Agenda

Danieli Andrade Department of Rheumatology, Faculty of Medicine of the University of São Paulo, São Paulo, Brazil

SWS-3(A) Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey

Zeynep B Erton Rheumatology, Hospital for Special Surgery, New York, USA

SWS-4(L) A Glimpse of APS ACTION Core Laboratory Activities

Laura Bertolaccini
Hannah Cohen

King's College London
University College London Hospitals and University College London

SWS-5(A) Lupus Anticoagulant test by Taipan snake venom time/Ecarin time (TSVT/ET): Performance Assessment by APS ACTION Core Laboratories

Maria Efthymiou

University College London, London, United Kingdom/University College London Hospitals NHS Foundation Trust, London, United Kingdom

SWS-6(L) Collaborative efforts of APS ACTION and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non-enzyme-linked immunosorbent assay antiphospholipid antibody

Katrien Devreese

Ghent University Hospital

L = Lecture, A = Abstract
SWS1, 4 = 10min., SWS2, 3, 5, 6 = 15min.

12:10-13:00 Luncheon Seminar 4

Chair : Tsuneyo Mimori (Kyoto University / Takeda Clinic for Rheumatic Diseases)

LS4 Current Treatment of Rheumatoid Arthritis

Akio Morinobu

Department of Rheumatology, Kyoto University Hospital

Co-Sponsored by Mitsubishi Tanabe Pharma

13:20-14:40 Workshop 12: Evolving APS Classification: Insights from Cutting-Edge Research

Chair : Doruk Erkan (Hospital for Special Surgery)

Denis Wahl (University of Lorraine)

WS12-1(L) The 2023 ACR/EULAR APS Classification Criteria: A Step Forward for Research

Stéphane Zulily

Department of vascular medicine, Lorraine University, Nancy, France

WS12-2(L) Pitfalls of the 2023 ACR/EULAR antiphospholipid syndrome Classification Criteria

Munther A Khamashta

Scientific Director, Immunology, GSK, Dubai, United Arab Emirates

WS12-3(A) Real life application of the 2023 ACR-EULAR classification criteria for obstetric antiphospholipid syndrome. A critical view of the criteria

sebastian udry

Fundacion Respirar research centre, Buenos Aires, Argentina

**WS12-4(A) QUADRUPLE ANTIPHOSPHOLIPID ANTIBODY POSITIVITY IS
ASSOCIATED WITH ACCRUAL DAMAGE IN ANTIPHOSPHOLIPID
SYNDROME SUBSETS**

Ariela Hoxha

Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED, University of Padua, Padua, Italy

L = Lecture (20 min), A = Abstract (15 min)

16:10-17:30 Symposium 4: JSTH and Japan APS-WS: Collaborative Advances in Antiphospholipid Research

Chair : Masahiro Ieko (Sapporo University of Health Sciences)

Eriko Morishita (Kanazawa University)

S4-1 Efforts Toward Standardization of Lupus Anticoagulant Testing in Japan

Naoki Tokunaga

Department of Clinical Laboratory, Kawashima Hospital, Tokushima, Japan

S4-2 Recent Advances in Clinical and Laboratory Standardization of Antiphospholipid Syndrome: Collaborative Achievements from the JSTH SSC and APS-WS in Japan

Kenji Oku

Tokai University School of Medicine, Isehara, Japan

S4-3 Collaborative efforts in Japan for alignment of diagnostic thresholds for antiphospholipid antibody assays and assessment of alternative threshold for improved screening of anti-phospholipid syndrome

Risa Kaneshige

Department of Laboratory Science, Faculty of Health Science, Yamaguchi University Graduate School of Medicine, Ube, Japan

17:45-19:15 **Poster 1: APS: basic science****P1-1 CUTANEOUS MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME**

Tatiana Reshetnyak Laboratory of thromboinflammation, V.A.Nasonova Research Institute of Rheumatology, Moscow, Россия

P1-2 Health information-seeking behaviour in patients with antiphospholipid syndrome: a Scoping review and original data

Mickaël Noyé Service de Médecine Vasculaire et Centre de Référence Constitutif des Maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte, CHRU de Nancy, Nancy, France./Department of Haemostasis, CHRU de Nancy, Nancy, France

P1-3 Serum calprotectin in antiphospholipid syndrome (APS)

Tatiana Reshetnyak Department of Thromboinflammation, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia./Department of Rheumatology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia

P1-4 Citrullinated histone H3 in antiphospholipid syndrome (APS)

Tatiana Reshetnyak Department of Thromboinflammation, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia./Department of Rheumatology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia

P1-5 Longitudinal Prognosis in Antiphospholipid Syndrome: Insights from a Large Chinese Cohort

Jiuliang Zhao Department of Rheumatology and Clinical Immunology, Department of Internal Medicine, Peking Union Medical College Hospital, Beijing, China./Department of Rheumatology and Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China./Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

P1-6 Daratumumab monotherapy regulates inflammatory, coagulative and endothelial response in Secondary Antiphospholipid Syndrome

Alice Barinotti Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

P1-7 Neutrophil extracellular traps induced by anti-phosphatidylserine/prothrombin antibodies promote platelet activation and contribute to thrombosis in antiphospholipid syndrome

Suishin Arai Department of Medical Laboratory Science, Faculty of Health Sciences, Hokkaido University, Sapporo, Japan

P1-8 Caveolin-1 as a marker of endothelial damage in primary APS nephropathy

Alice Barinotti Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

P1-9 Pulmonary embolism, hypercholesterolemia and lupus anticoagulant are associated with impaired quality of life in patients with antiphospholipid syndrome

Soraya Adjibade Vascular Medicine Division, French National Referral Center for Rare Systemic and Autoimmune Diseases, Université de Lorraine, Inserm, DCAC, and CHRU-Nancy, Vandoeuvre-les-Nancy, France

P1-10 B Cell-Mediated Immune Evasion via HLA-E/NKG2A Axis Drives Autoreactive B Cell Maturation in Antiphospholipid Syndrome

Haoyu Pan Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

P1-11 Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy

Shuyi Yu Department of Rheumatology and Immunology, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China

P1-12 Targeting the YAP1-CCN2 Signaling to Alleviate APS vasculopathy: Identification of Toosendanin as a Therapeutic Candidate

Zhixia Yang Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

P1-13 Mechanisms sensitive to different drugs mediate the platelet pro-adhesive/-thrombotic phenotype in anti-phospholipid syndrome

Pierluigi Meroni IRCCS Istituto Auxologico Italiano, Milan, Italy

P1-14 Systemic autoimmune rheumatic diseases and pregnancy: the role of antiphospholipid antibodies and complement in determining pregnancy outcome

Pierluigi Meroni IRCCS Istituto Auxologico Italiano, Milan, Italy

P1-15 Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository

Hannah Cohen Department of Haematology, University College London, London, United Kingdom/University College London Hospitals NHS Foundation Trust, London, United Kingdom

P1-16 Clinical Associations of IgA Antiphospholipid Antibodies in APS and SLE: A Study of Prevalence and Significance

Hannah Cohen Department of Haematology, University College London, London, United Kingdom/University College London Hospitals, London, United Kingdom

P1-17 Beta-2 glycoprotein I (β 2GP I) and its interacting molecules: Drivers of Endothelial Injury and Thrombosis in Antiphospholipid Syndrome

Ruiying Wang Department of Pathophysiology, School of Preclinical Medicine, Zunyi Medical University, Zunyi, China

P1-18 The pathological role of IgM anti-cardiolipin and IgM anti- β 2 glycoprotein I in the classification of antiphospholipid syndrome

Francesc Miro-Mur Systemic Autoimmune Diseases, Vall d'Hebron Institut de Recerca (VHIR),
Barcelona, Spain

P1-19 Monocyte epigenetic signatures from OAPS and TAPS patients are modified by aPL stimulation

Francesc Miro-Mur Systemic Autoimmune Diseases, Vall d'Hebron Institut de Recerca (VHIR),
Barcelona, Spain

P1-20 Aberrant Expression of Alpha Defensin 1 in Antiphospholipid Syndrome

Yuebing Wang Department of Rheumatology and Immunology, Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Beijing, China

17:45-19:15 **Poster 2: APS: laboratory tests**

P2-1 Impact of increased patient plasma ratio on APTT mixing test interpretation: A multi-index comparison

Yuya Maki Department of Clinical Laboratory Medicine, Tohoku University Hospital,
Sendai, Japan

P2-2 Neutralisation of Direct Xa inhibitors in plasma prior to lupus anticoagulant testing. Data from a large scale (UK NEQAS Blood Coagulation) field study

Christopher Reilly-Stitt UK NEQAS for Blood Coagulation, Sheffield, UK

P2-3 Clinical characteristics of plasma antiphospholipid antibodies in relation to reagent-dependent APTT abnormality

YOSHIKO KAGA Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University, Sendai, Japan

P2-4 Open - label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of Antiphospholipid Syndrome: Laboratory Preliminary Results

Massimo Radin Department of Clinical and Biological Sciences, University of Turin, Turin,
Italia

P2-5 The concentration and composition of phospholipids and the type of activator affected lupus anticoagulant sensitivity in thrombin generation assay

Osamu Kumano Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Takamatsu, Japan

**P2-6 Answering Seronegative Gap in Antiphospholipid Syndrome (APS):
Meta-analysis of Noncriteria Antiphospholipid Antibody Prevalence**

Perdana Aditya Rahman Internal Medicine, Universitas Brawijaya, Malang, Indonesia／Lupus, Autoimmune, Rheumatic and Allergy Study Group, Universitas Brawijaya, Malang, Indonesia

P2-7 Extra-criteria Antiphospholipid Antibodies Contribute to Non-thrombotic Clinical Manifestations in APS: a Large Single-center Cohort study in China

Jiuliang Zhao Department of Rheumatism and Immunology, Peking Union Medical College Hospital, Beijing, China

P2-8 Development of practical dilute prothrombin time assay with high sensitivity and specificity for detecting lupus anticoagulant

Masato Matsuda Department of Clinical Laboratory Sciences, Fukushima Medical University, Fukushima, Japan／Medical Laboratory Division, Niigata University Medical and Dental Hospital, Niigata, Japan

P2-9 Diagnostic value of IgM antiphospholipid antibodies as a single and combined serological marker in pediatric antiphospholipid syndrome

Eliana Annetta Laboratorio de Hemostasia y Trombosis, Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina

P2-10 Performance Evaluation of a New Multi-Analyte Assay for the Detection of Antiphospholipid Antibodies

Laura Martinez-Prat R&D, Werfen, Barcelona, Spain

P2-11 Evaluation of a novel particle based multi-analyte technology for the detection of anti-phospholipid antibodies of the IgA isotype

Laura Martinez-Prat Research and Development, Werfen, San Diego, United States

P2-12 Isolated IgM anticardiolipin and/or anti- β 2-glycoprotein I positivity - real-world data from a multicenter cohort

Mirjana Zlatković Švenda Department of Rheumatology, Institute of Rheumatology, Belgrade, Serbia／Faculty of Medicine, University of Belgrade, Belgrade, Serbia／Faculty of Medicine Foča, University of East Sarajevo, Foča, Republic of Srpska, Bosnia and Herzegovina

P2-13 Diagnostic performance assessment and biomarker detection rate of PMAT and ELISA assays for APS

Alejandro Figueroa-Lara Market Access, Werfen, San Diego, United States

P2-14 The association between phosphatidylserine dependent antiprothrombin antibodies (aPS/PT) and clinical domain scores in the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome

Mitsutaka Yasuda Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

P2-15 Comparison of a novel particle-based multi-analyte technology and routine methods for the detection of anti-phospholipid antibodies in an Australian Cohort

Laura Martínez-Prat Autoimmunity Research Unit, Werfen, Barcelona, Spain

P2-16 Diagnostic performance of anti-cardiolipin and anti-B2GPI IgG and IgM using a chemiluminescence assay: a meta-analysis

Carmen Andalucia Research and Development, Headquarters & Technology Center Autoimmunity, Werfen, San Diego, USA

P2-17 The Prevalence of Non-Conventional Antibodies in Antiphospholipid Syndrome: A Case-Control Study

Yousef atiea Al rimawi Department of rheumatology, Hamad Medical Corporation, Doha, Qatar

P2-18 ANTIOPHOSPHOLIPID ANTIBODIES PROFILE IN SAMPLES OF PATIENTS WITH OBSTETRIC COMPLICATIONS ATTENDED AT A GENERAL HOSPITAL

Agustina Negro Juan Fernández Hospital, Buenos Aires, Argentina

P2-19 Evaluation of antiphosphatidylserine/prothrombin (anti-PS/PT) IgG & IgM ELISA for potential role in Antiphospholipid syndrome investigations

Kieron Hickey Sheffield Haemophilia and Thrombosis Centre, South Yorkshire and Bassetlaw Pathology, Sheffield, UK

P2-20 The role of normalised APTT ratios in Lupus Anticoagulant investigations

Jessica A Creaghan Coagulation Department, Sheffield Haemostasis and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, United Kingdom

P2-21 A method comparison of the Dilute Russell's Viper Venom Time (DRVVT) on the Sysmex CS 5100 and the Sysmex CN 6000 using Siemens (UK) LA1 and LA2 reagents

Laura Marley Coagulation Laboratory, Sheffield Teaching Hospitals, Sheffield, England

P2-22 Use of mixing studies in lupus anticoagulant testing for patients treated with vitamin K antagonists

Hazel Medforth Coagulation Laboratory, Sheffield Teaching Hospitals FT, Sheffield, United Kingdom

P2-23 Establishment and Initial Findings of The Japanese Registry of Patients with Antiphospholipid Syndrome (J-RAPS)

Maria Tada Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

P2-24 Potential of Serum Anti- β 2-GPI/HLA-DR Antibody as a Novel Sensitive Marker for Reproductive Function, Including Ovarian Reserve and Implantation Capacity in Infertility Screening

Hirotaka Matsumi Matsumi Ladies Clinic, Tokyo, Japan

P2-25 Impact of a fixed 40-unit threshold for APS classification in the absence of standardized calibrators

Ariadna Anunciacion-Llunell Systemic Autoimmune Diseases, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

P2-26 CLIA remains a valuable tool for APS diagnosis with a need of sex-specific cut-offs

Ariadna Anunciacion-Llunell Systemic Autoimmune Diseases, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

17:45-19:15 **Poster 3: thrombotic APS**

P3-1 High incidence of Antiphospholipid syndrome in post-acute phase of severe COVID-19 could explain the post-COVID syndrome

Mirjana Zlatkovic-Svenda Rheumatology, Institute of Rheumatology, Belgrade, Serbia/University of Belgrade School of Medicine, Belgrade, Serbia/University of East Sarajevo, Faculty of Medicine Foča, Republika Srpska, Bosnia and Herzegovina

P3-2 ASSESSMENT OF THE 2023 ACR/EULAR ANTIOPHOSPHOLIPID SYNDROME CLASSIFICATION CRITERIA IN A BRAZILIAN PRIMARY ANTIOPHOSPHOLIPID SYNDROME COHORT

Guilherme R de Jesús Department of Rheumatology, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brasil

P3-3 CHARACTERISTICS OF THE PRIMARY ANTIOPHOSPHOLIPID SYNDROME PATIENTS INCLUDED IN THE BRAZILIAN REGISTRY OF ANTIOPHOSPHOLIPID (BRAPS)

Danieli C O Andrade Department of Rheumatology, Universidade de São Paulo, São Paulo, Brazil

P3-4 The impact of sedentary behavior and physical activity level on clinical parameters and quality of life in patients with primary antiphospholipid syndrome (PAPS)

DANIELI C O ANDRADE DEPARTAMENT OF RHEUMATOLOGY, SAO PAULO UNIVERSITY, SAO PAULO, BRAZIL

P3-5 Thrombotic antiphospholipid syndrome: recurrent thromboses

Tatiana Reshetnyak Laboratory of Thromboinflammation, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation/Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, Moscow, Russian Federation

P3-6 Increased Venous Wall Thickness in Antiphospholipid Syndrome: A Potential Diagnostic Tool?

AB Kelesoglu Dincer Department of Rheumatology, Etlik City Hospital, Ankara, Turkey/Department of Rheumatology, The Pearl International Hospital, Doha, Qatar

P3-7 Antiphospholipid antibodies in patients with ovarian cancer: A prospective pilot study

Takashi Mitamura Department of Obstetrics and Gynecology, Hokkaido University Faculty of Medicine, Hokkaido University, Sapporo, Japan

P3-8 Recurrent Transient Vision Loss at High Altitudes in a Patient with Persistent Lupus Anticoagulant Positivity

Doruk Erkan Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA

P3-9 Three distinct clinical subgroups of antiphospholipid antibodies-associated thrombocytopenia with different prognosis: a prospective cohort study with cluster analysis

Juliang Zhao Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, China, Beijing

P3-10 Efficacy and Safety of Belimumab in Antiphospholipid Syndrome: A Retrospective Cohort Study

Xiaohan Wei Department of Rheumatology and Immunology, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China

P3-11 Is there a window of opportunity for DOACs in APS patients?

Nataliya V. Seredavkina V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

P3-12 Dynamic Increase in Monocyte/HDL-Cholesterol Ratio Precedes Thrombotic Recurrence in Antiphospholipid Syndrome

Ryo Hisada Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

P3-13 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME (CAPS): DESCRIPTIVE ANALYSIS FROM ARGENTINEAN REGISTRY OF ANTIPHOSPHOLIPID ANTIBODIES

Paula Alba Moreyra Antiphospholipid Syndrome Study Group, Argentinean Society of Rheumatology, Cordoba, Argentina

P3-14 Exploring the Significance of Antiphospholipid Antibody in Chronic Thromboembolic Pulmonary Hypertension

Dabuxilite Bayartaikishigtai Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovascular Diseases, Beijing, China

P3-15 VITAMIN D LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME

Paula Alba Rheumatology Unit, Córdoba Hospital, Córdoba State University, Argentina

P3-16 Acute Pulmonary Embolism in a Young Woman with SLE and Triple Positive Antiphospholipid Antibodies: A Case Highlighting the Role of Multidisciplinary Management

Faisal Parlindungan Rheumatology Unit, Department of Internal Medicine, Mayapada Kuningan Hospital, Jakarta, Indonesia

P3-17 Suspected seronegative APS in a case of thrombotic thrombocytopenia – don't miss anti-PF4 antibodies!

Mickaël Noyé Vascular Medicine Division, Nancy University Hospital, Nancy, France/Laboratory Haematology, Nancy University Hospital, Nancy, France

P3-18 ASSESSMENT OF THE 2023 ACR/EULAR ANTIPHOSPHOLIPID SYNDROME CLASSIFICATION CRITERIA: ANALYSIS FROM ARGENTINEAN REGISTRY OF ANTIPHOSPHOLIPID ANTIBODIES

Paula Alba Moreyra Antiphospholipid Syndrome Study Group, Argentine Society of Rheumatology, Buenos Aires, Argentina

P3-19 The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

Doruk Erkan, MD, MPH Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA

P3-20 The Prevalence and Clinical Significance of IgA Anticardiolipin Antibody and Anti- β_2 -Glycoprotein-I Antibody Isotype in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinic

Doruk Erkan, MD, MPH Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA

P3-21 Consistently present? Exploring intra-individual variability in antiphospholipid antibodies

Maarten Limper Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

P3-22 IMPORTANCE OF PRE-TRANSPLANT RECOGNITION OF ANTIPHOSPHOLIPID SYNDROME

Danieli Castro Oliveira de Andrade Department of Rheumatology, Faculty of Medicine of the University of São Paulo, São Paulo, Brazil

P3-23 Anticoagulation-refractory Seronegative-Antiphospholipid antibody syndrome - A rare case report with literature review

Veerendra Chadachan General Medicine (Vascular Medicine), Tan Tock Seng Hospital, affiliated to YLL School of Medicine, Singapore, Singapore

P3-24 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Crovalimab as Add-On Therapy in Patients with Antiphospholipid Syndrome and Recurrent Thrombosis

Doruk Erkan

Weill Cornell Medical, New York, USA

17:45-19:15 **Poster 4: obstetric APS**

P4-1 Pravastatin for the Prevention and Treatment of Adverse Pregnancy Outcomes in Antiphospholipid Syndrome: A Single-Center Case Series in Japan

Akitsu Higuchi

Division of Maternal medicine, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan

P4-2 Pregnancy outcomes in women with antiphospholipid syndrome (APS)

Tatiana M Reshetnyak

Laboratory of Throinflammation, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation/Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, Moscow, Russian Federation

P4-3 Pregnancy outcomes in women with antiphospholipid antibodies (aPL) depending on therapy

Tatiana Reshetnyak

Laboratory of Throinflammation, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation/Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, Moscow, Russian Federation

P4-4 A case of pregnancy with suspected APS following to positive serologic test for syphilis

Hironobu Hyodo

Department of Obstetrics and Gynecology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan

P4-5 Heparin Plus Aspirin: A Rescue Strategy for Recurrent Pregnancy Loss Unresponsive to Low-Dose Aspirin

Tomoko Ichikawa

Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo, Japan

P4-6 Early recurrent miscarriage: which is the degree of association with antiphospholipid antibodies and when should it be studied?

Sebastian Udry

Fundacion Respirar research centre, Buenos Aires, Argentina

P4-7 Assessment of Antiphospholipid Antibodies in Patients with Recurrent Pregnancy Loss

Savvy Benipal

Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, USA

P4-8 A Retrospective Review of Antiphospholipid syndrome in pregnancy

Liying Yang

Obstetrics & Gynaecology, Singapore General Hospital, Singapore, Singapore

P4-9 Treatment Outcomes and Preventive Strategies of Intralipid Therapy for Recurrent Pregnancy Loss Through Immune Modulation
Hirotaka Matsumi Matsumi Ladies Clinic, Tokyo, Japan

P4-10 ACR/EULAR APS classification criteria affect enrolment of obstetric APS patients. A pilot test with the European Registry of Obstetric APS(EUROAPS)
Joana Marques-Soares Systemic Autoimmune Diseases, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain/Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain

P4-11 Pregnancy Outcomes in Women with Primary Antiphospholipid Syndrome: 23 Years of Experience of a Referral Center in Brazil
Guilherme R R de Jesus Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil

P4-12 Low frequency of antiphospholipid antibodies and adverse pregnancy outcomes in patients with recurrent pregnancy loss
Guilherme R R de Jesus Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil

P4-13 Antiphospholipid Syndrome (APS)in pregnancy: an update of pregnancy management, maternal and perinatal outcome in one Public Hospital in Argentina
Beatriz E Grand Department of Fetal and Maternal Medicine. Hematology and Obstetric Division, Hospital Juan A Fernandez. University of Buenos Aires, Buenos Aires, Argentina

17:45-19:15 **Poster 5: Lupus and autoimmune diseases**

P5-1 The Impact of Antiphospholipid Antibodies on Heart Valve involvements in Systemic Lupus Erythematosus: based on CSTAR cohort
Jiuliang Zhao Peking Union Medical College Hospital, Beijing, China/National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China/State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China

P5-2 Sequential development of autoimmune haemolytic anaemia and pure red cell aplasia in a patient with primary antiphospholipid syndrome
Kazuro Kamada Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

P5-3 Belimumab in refractory and/or non-criteria manifestations of antiphospholipid syndrome: ad interim analysis on Quality-of-Life changes from the BLAST trial
Lois Ira M. Capulong Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

P5-4 Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus
Jinyi Qian Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China

P5-5 CAPSTONE I (Chinese Antiphospholipid Syndrome cohort cOllaborative NEtworks): Family History in Relation to Clinical Manifestations
Zixin Wang Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China

P5-6 Monitoring COrplement levels during pRegnancy in prospectively followed systemic Lupus erythematosus patients: a post-hoc analysis of the CORAL study focusing on antiphospholipid antibodies
Irene Cecchi Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

P5-7 Pediatric antiphospholipid syndrome in a large tertiary center: Is there a need for criteria for pediatric APS?
Olivia A Kwan Department of Pediatric Rheumatology, Baylor College of Medicine, Houston, Texas

P5-8 CAPSTONE: A multicenter prospective aPLs positive cohort from China
Jiuliang Zhao Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China

P5-9 The impacts of antiphospholipid antibodies on pregnancy outcomes in systemic lupus erythematosus
Jiuliang Zhao Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China/National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China/Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

P5-10 Longitudinal fluctuations of antiphospholipid antibodies and vascular events in a cohort of newly diagnosed Systemic Lupus Erythematosus: a two year follow up study
RITESH KUMAR MISHRA Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

P5-11 Successful Treatment of Refractory Eosinophilic Granulomatosis with Polyangiitis and Secondary Obstetric Antiphospholipid Syndrome with Rituximab: A Case Report
Eladio G M Anino V Division of Rheumatology, Department of Medicine, Philippine General Hospital, Manila, Philippines

P5-12 Lupus Anticoagulant as a Confounding Factor in the Detection of Autoantibodies Against Coagulation Factor V
Kazumasa Ohmura Institute of Preventive Medical Sciences, Health Sciences University of Hokkaido, Sapporo, Japan

P5-13 Tcf1 regulates the differentiation of B1 cells and the secretion of anticardiolipin antibodies involved in the development of SLE

Hui Chen

Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China

09:00-10:20 **Workshop 13: Thrombotic APS: Decoding the Mechanisms Behind Autoimmunity and Thrombosis**

Chair : Kenji Oku (Tokai University)

Paul Fortin (CHU de Québec - Université Laval)

WS13-1(L) New mechanisms of microvascular APS

Jason Knight

University of Michigan Medical School, USA

WS13-2(L) Complement Activation in the Pathogenesis of Antiphospholipid Syndrome (APS)

Kenji Oku

Tokai University School of Medicine, Isehara, Japan

WS13-3(A) Withdrawn

WS13-4(A) Glycolysis Activation by Antiphospholipid Antibodies in Monocytes: A Potential Therapeutic Target in Antiphospholipid Syndrome

Ryo Hisada

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

L = Lecture (20 min), A = Abstract (15 min)

09:00-10:20 **Workshop 14: Obstetric APS Clinical Insights**

Chair : Henriette Svarre Nielsen (University of Copenhagen)

Takeshi Nagamatsu (International University of Health and Welfare)

WS14-1(L) Obstetric Antiphospholipid Syndrome: patient impact and ESHRE guideline advices

Mariëtte Goddijn Amsterdam UMC, Amsterdam, Netherlands

WS14-2(L) Autoantibodies in Pregnancy: Diagnostic and Predictive Perspectives

Hiroyuki Yoshihara Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan / Division of Biomedical Sciences, Clinical Science Research Laboratories, Warwick Medical School, University of Warwick, Coventry, United Kingdom

WS14-3(A) Sensitivity of the ACR/EULAR classification criteria in a multicenter Italian cohort of patients with obstetric antiphospholipid syndrome (OAPS): implications for clinical practice

Cecilia Nalli RHEUMATOLOGY AND CLINICAL IMMUNOLOGY, ASST SPEDALI CIVILI OF BRESCIA, BRESCIA, ITALY

WS14-4(A) Thrombotic events, long term follow up in antiphospholipid antibodies positive patients with recurrent pregnancy loss

Minami Ashio *Obstetrics and Gynecology, Nagoya City University, Aichi, Japan*

L = Lecture (20 min), A = Abstract (15 min)